Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K3 | P46734 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 15/20 | 0.50 |
| ▸ | CA9 | Q16790 | 15/20 | 0.50 |
| ▸ | CA1 | P00915 | 13/20 | 0.50 |
| ▸ | CA12 | O43570 | 11/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11909224 | 0.87 | MAP2K3 (0.51) | MAP2K3PTGS2 | |
| SCHEMBL11907320 | 0.83 | MAP2K3 (0.51) | MAP2K3CA2CA9CA1CA12 | |
| SCHEMBL11908303 | 0.81 | MAP2K3 (0.73) | MAP2K3 | |
| SCHEMBL11908374 | 0.80 | MAP2K3 (0.77) | MAP2K3CYP2C19 | |
| SCHEMBL11907713 | 0.78 | MAP2K3 (0.76) | MAP2K3CYP2C19 | |
| SCHEMBL11907875 | 0.75 | MAP2K3 (0.51) | MAP2K3 | |
| SCHEMBL11909565 | 0.73 | ATR (0.55) | MAP2K3GSK3BJAK2 | |
| SCHEMBL11909117 | 0.73 | MAP2K3 (0.53) | MAP2K3 | |
| SCHEMBL11908776 | 0.73 | MAP2K3 (0.53) | MAP2K3 | |
| SCHEMBL11909201 | 0.72 | ATR (0.43) | MAP2K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MAP2K3 197/4885CA2 2979/4885CA9 3709/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MAP2K3 197/4885CA2 2979/4885CA9 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.